CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 21 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2015. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $3,610,000 | -41.4% | 1,000,000 | 0.0% | 0.19% | -30.6% |
Q3 2016 | $6,160,000 | +66.5% | 1,000,000 | 0.0% | 0.27% | +51.4% |
Q2 2016 | $3,700,000 | -26.6% | 1,000,000 | 0.0% | 0.18% | -39.3% |
Q1 2016 | $5,040,000 | -36.4% | 1,000,000 | 0.0% | 0.30% | -42.4% |
Q4 2015 | $7,930,000 | -2.0% | 1,000,000 | 0.0% | 0.51% | -26.1% |
Q3 2015 | $8,090,000 | -28.6% | 1,000,000 | +7.8% | 0.69% | -10.1% |
Q2 2015 | $11,326,000 | – | 927,609 | – | 0.77% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SV Health Investors, LLC | 2,857,667 | $4,572,000 | 5.05% |
Clarus Ventures, LLC | 2,752,488 | $4,404,000 | 3.28% |
SPHERA FUNDS MANAGEMENT LTD. | 388,030 | $621,000 | 0.12% |
Rhenman & Partners Asset Management AB | 310,756 | $497,000 | 0.08% |
BOSTON FAMILY OFFICE LLC | 24,467 | $39,000 | 0.01% |
OPPENHEIMER & CO INC | 90,000 | $144,000 | 0.00% |
Alyeska Investment Group, L.P. | 221,281 | $354,000 | 0.00% |
A.R.T. Advisors, LLC | 46,747 | $74,000 | 0.00% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 101,347 | $162,000 | 0.00% |
Acrospire Investment Management LLC | 680 | $1,000 | 0.00% |